Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder
NCT04779177
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
26
Enrollment
INDUSTRY
Sponsor class
Conditions
Schizophrenia
Pediatric
Interventions
DRUG:
Lumateperone 42 mg
DRUG:
Lumateperone 28 mg
Sponsor
Intra-Cellular Therapies, Inc.